In conclusion, immune checkpoints inhibitor therapy does not have a favorable prognosis in ovarian cancer patients, although the combination of anti-PD-1/PD-L1 agents with chemotherapy or PARPi can lead to increased response rates in selected patient populations. The gene discussed is CD274; the disease is ovarian cancer.